AZAlberto Carlos Moreno Zaconeta

Alberto Carlos Moreno Zaconeta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alberto Carlos Moreno Zaconeta has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuropsychomotor Development of Children Exposed to SARS-CoV-2 in Utero During COVID-19 Pandemic

    by Felipe Motta, Maria Eduarda Canellas-De-Castro, Geraldo Magela Fernandes, Lizandra Moura Paravidine Sasaki, David Alves de Araújo Júnior, Alberto Moreno Zaconeta, Ângelo Pereira da Silva, Ciro Martins Gomes, Cleandro Pires Albuquerque, Ismael Artur Costa-Rocha, et al.

    Introduction: Little is known about the effects of intrauterine exposure to SARS-CoV-2, especially on growth and neurodevelopment in children. Objective: We wished to verify the effect of intrauterine exposure to SARS-CoV-2 on neurological development in children. Methods: Infants born to mothers presenting with SARS-CoV-2 infection during pregnancy were enrolled in a prospective descriptive–analytical study involving outpatient appointments performed 6 and 12 months after birth. Their neurological development was assessed using the Bayley-III Scale, using a score of >85 as the cutoff threshold for identifying developmental delay. Differences between groups were assessed through an ANOVA, using Bonferroni correction for multiple comparisons. Regression models were employed to examine the associations between the Bayley-III scores and maternal features. Results: Two hundred and sixty-nine infants were evaluated, most of whom were born full-term and with birth weights appropriate for gestational age at delivery. Developmental delays were observed in 26% of the infants in at least one of the Bayley-III domains. The language domain was particularly affected, with impairments observed in children exposed to SARS-CoV-2 closer to the time of delivery. These findings were statistically significant (p < 0.05). Conclusions: Infants born to mothers presenting with SARS-CoV-2 infection during pregnancy presented developmental delays at 6 and 12 months, particularly in the language domain. These findings reinforce the relevance of long-term clinical follow-ups of newborns exposed to SARS-CoV-2 infection during pregnancy.


  • Open Access

    Violência contra a mulher: proposta de atividade simulada para o ensino do reconhecimento e abordagem

    by Juliana Arais Hocevar Kristoschek, Marina Mayumi Laranjeira Caldas Kamei, Thales Queiroz Souza, Ana Lídia Peixoto Monteiro Ramos, Natália Maia Braz Silveira, Alberto Zaconeta

    INTRODUÇÃO A Organização Mundial de Saúde (OMS) define a violência contra a mulher (VCM) como qualquer ato de violência de gênero que resulte ou possa resultar em danos ou sofrimentos físicos, sexuais ou mentais para as mulheres, inclusive ameaças de tais atos, coação ou privação arbitrária de liberdade, seja na vida pública ou privada.() Ela […] INTRODUÇÃO A Organização Mundial de Saúde (OMS) define a violência contra a mulher (VCM) como qualquer ato de violência de gênero que resulte ou possa resultar em danos ou sofrimentos físicos, sexuais ou mentais para as mulheres, inclusive ameaças de tais atos, coação ou privação arbitrária de liberdade, seja na vida pública ou privada.() Ela […]

  • Open Access

    How can we reduce maternal mortality due to preeclampsia? The 4P rule

    by Henri Augusto Korkes, Ricardo Carvalho Cavalli, Leandro Gustavo De Oliveira, José Geraldo Lopes Ramos, Sérgio Hofmeister de Almeida Martins Costa, Francisco Lázaro Pereira de Sousa, Edson Vieira da Cunha, Maria Rita de Souza Mesquita, Mário Dias Corrêa, Ana Cristina Pinheiro Fernandes Araújo, et al.

    In low and middle-income countries such as Brazil, most maternal deaths are related to hypertensive complications. Preeclampsia is the leading cause of maternal mortality and morbidity. Significant proportion is associated with the following factors: lack of identification of high-risk women, lack of adequate prevention, difficulty in maintaining a high-risk prenatal follow-up, delayed diagnosis, insecurity […] Abstract In low and middle-income countries such as Brazil, most maternal deaths are related to hypertensive complications. Preeclampsia is the leading cause of maternal mortality and morbidity. Significant proportion is associated with the following factors: lack of identification of high-risk women, lack of adequate prevention, difficulty in maintaining a high-risk prenatal follow-up, delayed diagnosis, insecurity […]


  • Open Access

    Gravidez não planejada no Brasil: estudo nacional em oito hospitais universitários

    by Tainá Vieira Nilson, Angélica Amorim Amato, Ceres Nunes Resende, Walquíria Quida Salles Pereira Primo, Roseli Mieko Yamamoto Nomura, Maria Laura Costa, Maria Lúcia Opperman, Marianna Brock, Alberto Trapani Junior, Lia Cruz Vaz da Costa Damasio, et al.

    OBJECTIVE: To estimate the prevalence of unplanned pregnancy in eight public university hospitals, distributed in the five regions that make up Brazil. METHODS: A secondary analysis of a national multicenter cross-sectional study, carried out in eight public university hospitals between June 1 and August 31, 2020, in Brazil. Convenience sample including women who gave birth within sixty consecutive days and met the following criteria: over 18 years old; gestational age over 36 weeks at delivery; with a single and live newborn, without malformations. RESULTS: Sample composed of 1,120 postpartum women, of whom 756 (67.5%) declared that the pregnancy had not been planned. The median prevalence of unplanned pregnancy was 59.7%. The prevalence of unplanned pregnancy across hospitals differed significantly: Campinas (54.8%), Porto Alegre (58.2%), Florianópolis (59%), Teresina (61.2%), Brasília (64.3%), São Paulo (64.6%), Campo Grande (73.9%) and Manaus (95.3%) (p < 0.001). Factors significantly associated with unplanned pregnancy were maternal age, black color, lower family income, greater number of children, greater number of people living in household, and not having a partner. CONCLUSION: In the studied sample, about two thirds of the pregnancies were declared as unplanned. The prevalence of unplanned pregnancies was related to social and demographic factors and varied significantly across the university hospitals evaluated.


  • Open Access

    Expert Recommendations on Monkeypox (MPX) in Pregnancy, Postpartum and Lactating Women

    by Rosiane Mattar, Antonio Rodrigues Braga Neto, Adriana Gomes Luz, Alan Hatanaka, Alberto Zaconeta, Cristina Aparecida Falbo Guazzelli, Evelyn Traina, Fernanda Spadotto Baptista, Gabriel Osanan, Geraldo Duarte, et al.

    In 2020, Brazil and the whole world faced the COVID-19 pandemic, which caused a high number of deaths. This disease was particularly severe for pregnant and postpartum women and determined a significant increase in the Maternal Death Ratio (MMR). To face the disease and assist health professionals in the qualification of the best care to the maternal-fetal binomial, the Ministry of Health and Febrasgo developed a working group formed by professors and researchers from several universities who worked to establish recommendations for the care of pregnant women and puerperal women by the time of the COVID-19 pandemic. In 2022, while we are still experiencing the COVID-19 pandemic, we are surprised by another disease caused by a virus that has been alarming the population and worrying public health authorities and gynecology and obstetrics societies in Brazil and worldwide. It is the infection that is caused by monkeypox virus (MPXV), which is still a not well-known disease, with many of its characteristics not well determined. The knowledge of this disease is fundamental for health professionals working in Obstetrics to plan forms of prevention, as well as the establishment of the diagnosis and treatment of the monkeypox (MPX) disease, preserving the health of the maternal-perinatal binomial. For this reason, the Brazilian Ministry of Health requested the same working group that acted diligently by the time of COVID-19 to establish recommendations for facing MPX, to provide adequate care for pregnant women and puerperal women. These recommendations, based on the knowledge that exists so far, are what guide these orientations and may change depending on new findings that may be presented over time. The MPXV was named after being identified in laboratory monkeys in 1958. The first case of this virus in humans was recorded in 1970 in a child in Congo and since then has become an endemic disease in West and Central Africa.[1] In 2003, the first cases were registered outside the African continent, in the United States,[2] [3] [4] but that was contained through hygienic measures and stock vaccines. In 2017, there was a major outbreak started in Nigeria and spread to some African countries. In early May 2022, another outbreak of MPXV was identified, this time in several countries outside the African continent, with fast dissemination of cases. As a result, on May 21, 2022, the World Health Organization (WHO) declared the existence of an emerging global outbreak of MPXV infection, and on July 23 has determined that this outbreak constituted a Public Health emergency of international concern. Pregnant women present clinically with similar characteristics to nonpregnant women, but may evolve with greater severity, being therefore considered a risk group. In addition to maternal clinical repercussions, there are also concerns specific to the pregnancy period, such as fetal vitality, the possibility of vertical transmission and perinatal outcome. It has been verified that MPXV infection can lead to adverse results in pregnancy, such as fetal death and spontaneous abortion.[5] [6] A recent publication on the evolution of pregnancy in 4 MPXV-infected women showed spontaneous 1st trimester abortion in 2 pregnant women, without testing of the conception products; an intrauterine death in the 2nd trimester, with clinical, histological and laboratory evidence of intrauterine fetal infection evidencing the very probable vertical transmission of the disease, and a pregnant woman with MPXV infection that evolved with full-term delivery of healthy conceptus.[7] Close and prolonged skin-to-skin contact, including during sexual activity, seems to be the main means of transmission of MPXV. There are suspicions of transmission of this virus by droplets and aerosols. There is also transmission through biting of rodent animals or even the ingestion of those animals. In addition, contagion by phositis, especially used clothing, can transmit the disease. The quick identification and isolation of affected individuals is fundamental to prevent the spreading of the disease.[8] Transmission of MPXV occurs in the phase of active skin lesions and only ends when they heal completely, which usually requires isolation of 21 to 28 days.[7] [9] [10] There are doubts as to whether the contagion could be prior to the phase of skin lesions, since viral DNA has already been identified in the blood and respiratory system of patients prior to the lesions.[5] [7] Sexual transmission has been discussed not only by contact, but also because the virus has been identified in seminal material.[5] [11] Patients with MPXV should be isolated in a separate area of their home or in hospital services, especially if they present extensive lesions and/or respiratory symptoms. Skin lesions should be covered (for example, with the use of long sleeves and trousers) to minimize the risk of contact. Everyone should wear a face mask in the presence of an infected person. Sexual abstinence is also recommended in the phase of unhealed lesions and condom use for any form of sexual act (anal, oral, or vaginal) in the 12 weeks following the healing of the lesions.[7] Most patients with MPXV will have mild disease and can be cared for at home, where they should remain isolated. Standard cleaning and disinfection procedures should be performed, taking care of clothes and used objects. The diagnosis of infection can be made by anamnesis and clinical findings, with epidemiological suspicion. The incubation period is, on average, 6 to 13 days, and can be from 5 to 21 days. Next to this, a prodromal period occurs, when fever, sweating, headache, myalgia, fatigue and lymphadenomegaly, which is quite characteristic of the disease, are manifested. About 1 to 3 days later, the rash, which usually affects the face, genitals, and extremities, and has a centrifugal character, appears. The lesion evolves from macules to papules, vesicles, pustules and, later, crusts.[3] In general, they are well circumscribed and deep, and develop umbilication. They can also be uniform or at different stages of evolution. Lesions are often painful until healing (which happens normally when they are itching). The severity criteria consider the number of lesions: Mild (< 25 skin lesions), Moderate (25–99), Severe (100–250) and very severe (> 250). Another severity criterium is when one of these signs is present: fever for > 7 days, cervical lymph node, persistent vomiting, dehydration, retrocular pain, respiratory failure, mental confusion, hepatomegaly, and sepsis. Confirmatory laboratory diagnosis of MPXV can be performed by real-time polymerase chain reaction (qPCR).[12] Sample collection should preferably be performed with swab of ulcerated lesions. If there are only vesicles, the sample can be obtained by means of fine needle puncture, with extreme caution to avoid accidents that allow contagion. If there are only crusts, the material can be obtained by swab or by collection of small fragments. These samples should be stored in dry sterile vials without any preserving liquid. In individuals in whom MPXV is suspected, without any clinical suspicion, oral swab should be tested and vaginal or anal swab may be considered.[13] Blood samples are oriented for differential diagnosis and/or concomitance of other diseases that could cause lesions, such as syphilis, acquired immunodeficiency syndrome, and herpetic infection.[12] [13] Although the disease is most of the time self-limited and with spontaneous cure, in some cases there may be a need for specific drug treatment. Most of the time, there is only indication of symptomatic treatment for fever and pain with dipyrone, acetaminophen, or even opiate derivatives in the most severe pain conditions. In cases with more important lesions, the use of antibiotics may be indicated to prevent secondary bacterial infection: systemic amoxicillin and ocular chloramphenicol. There are some patients who have worsening of the condition, and in these circumstances, antivirals are indicated. Antiviral drugs: Tecovirimat (TPOXX), cidofovir (Vistide) and brincidofovir (Tembexa) have been considered. About 5% of patients with MPXV require antivirals.[11] [14] There are still no well-established protocols for their use in pregnancy. Immunoglobulin (VIG), a mixture of purified blood antibodies of individuals immunized with the smallpox vaccine, has already been used for the prevention/treatment of MPXV. There is no evidence on its effectiveness; however, it has already been considered as prophylaxis in exposed individuals with severe immunodeficiency as a prevention/treatment of MPXV. There are two vaccines developed to fight human smallpox, which are capable of inducing protective antibodies against MPXV. However, they are not available in Brazil and there are not enough doses for mass vaccination. The first is ACAM2000, with live vaccinia attenuated but replicating virus, applied in a single dose and with immune response 4 weeks after application. Because it is a live virus vaccine, it is contraindicated for individuals with immunodeficiency and pregnant women. The second vaccine is Modified Ankara (MVA-BN), produced by Bavarian Nordic, with live, attenuated, nonreplicating virus[15] is sold in Europe as Imvamune or Imvanex and in the United States as Jynneos. It has efficacy of 85%.[16] It can be used in immunosuppressed patients. It is applied in two doses with an interval of 4 weeks, and its protection begins 2 weeks after the second dose. Article published online: 29 December 2022 © 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil


  • Open Access

    Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection (PROUDEST Trial): Protocol for a Multicenter, Prospective Cohort Study

    by Geraldo Magela Fernandes, Felipe Motta, Lizandra Moura Paravidine Sasaki, Ângelo Pereira Da Silva, Andreza Monforte Miranda, Aleida Oliveira De Carvalho, Ana Paula Monteiro Gomides, Alexandre Anderson De Sousa Munhoz Soares, Agenor De Castro Moreira Dos Santos Jr, Caroline De Oliveira Alves, et al.

    Background: A growing body of evidence suggests that SARS-COV-2 infection during pregnancy may affect maternal-fetal outcomes and possibly result in implications for the long-term development of SARS-CoV-2–exposed children. Objective: The PROUDEST (Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection Study) is a multicenter, prospective cohort study designed to elucidate the repercussions of COVID-19 for the global health of mothers and their children. Methods: The PROUDEST trial comprises 2 prospective, sequential substudies. The PREGNANT substudy will clinically assess the effects of SARS-CoV-2 infection on pregnancy, childbirth, and puerperium from a mechanistic standpoint to elucidate the pregnancy-related inflammatory and immunological phenomena underlying COVID-19. Pregnant women aged 18-40 years who have been exposed (proven with laboratory tests) to SARS-CoV-2 (group A; n=300) will be compared to control subjects with no laboratory evidence of in-pregnancy exposure to the virus (group B; n=300). Subjects exposed to other infections during pregnancy will be excluded. The BORN substudy is a long-term follow-up study that will assess the offspring of women who enrolled in the prior substudy. It will describe the effects of SARS-CoV-2 exposure during pregnancy on children’s growth, neurodevelopment, and metabolism from birth up to 5 years of age. It includes two comparison groups; group A (exposed; n=300) comprises children born from SARS-CoV-2–exposed pregnancies, and group B (controls; n=300) comprises children born from nonexposed mothers. Results: Recruitment began in July 2020, and as of January 2021, 260 pregnant women who were infected with SARS-CoV-2 during pregnancy and 160 newborns have been included in the study. Data analysis is scheduled to start after all data are collected. Conclusions: Upon completion of the study, we expect to have comprehensive data that will provide a better understanding of the effects of SARS-CoV-2 infection and related inflammatory and immunological processes on pregnancy, puerperium, and infancy. Our findings will inform clinical decisions regarding the care of SARS-CoV-2–exposed mothers and children and support the development of evidence-based public health policies. Trial Registration: Brazilian Register of Clinical Trials RBR65QXS2; https://ensaiosclinicos.gov.br/rg/RBR-65qxs2 International Registered Report Identifier (IRRID): DERR1-10.2196/26477


  • Open Access

    Impact of the COVID-19 Pandemic on Maternal Anxiety in Brazil

    by Roseli Nomura, Isabela Tavares, Ana Carla Ubinha, Maria Laura Costa, Maria Lucia Opperman, Marianna Brock, Alberto Trapani, Lia Damasio, Nadia Reis, Vera Borges, et al.

    Background: The coronavirus disease 2019 (COVID-19) pandemic may have an effect on maternal anxiety and influence postpartum experience. Objective: To study the prevalence of maternal anxiety in late pregnancy in the context of the COVID-19 outbreak in Brazil and to analyze its association with maternal knowledge and concerns about the pandemic. Methods: This was a national multicenter cross-sectional study performed in 10 different public university hospitals, between 1 June and 31 August 2020, in Brazil. The inclusion criteria were: maternal age more than 18 years; gestational age more than 36 weeks at childbirth; single alive newborn without malformations; and absence of mental disorders. We applied a structured questionnaire to explore the knowledge and concerns about COVID-19. Maternal anxiety was assessed using the Beck Anxiety Inventory (BAI). Results: Of the 1662 women interviewed, the BAI score in late pregnancy indicated that 13.9% presented moderate and 9.6% severe maternal anxiety. Moderate or severe maternal anxiety was independently associated with the fear of being unaccompanied at childbirth (aOR1.12, 95% CI 1.10–1.35), and independent protective factors were confidence in knowing how to protect oneself from COVID-19 (aOR0.89, 95% CI 0.82–0.97) and how to safely breastfeed (aOR0.89, 95% CI 0.83–0.95). Conclusion: The COVID-19 pandemic has a significant impact on maternal anxiety.


  • Open Access

    Medical Residency in Gynecology and Obstetrics in Times of COVID-19: Recommendations of the National Specialized Commission on Medical Residency of FEBRASGO

    by Gustavo Salata Romão, Lucas Schreiner, Claudia Lourdes Soares Laranjeiras, Zsuzsanna Ilona Katalin de Jarmy Di Bella, Raquel Autran Coelho, Maria da Conceição Ribeiro Simões, Mario Dias Correa Júnior, Milena Bastos Brito, Marcelo Luis Steiner, Alberto Trapani Junior, et al.

    The COVID-19 pandemic (Coronavirus Disease 2019) has affected residencies training around the world. In the light of responses to the pandemic, many medical residencies are being forced to reorganize their rotations. These changes include a reduction in the operating room and outpatient care training, and the cancellation of some activities such as visits to the wards, simulation sessions, among others.[1] According to recommendations of the American College of Surgeons (ACS),[1] elective surgeries should be postponed during the pandemic. The major aspects that support this position include difficulties with mobilizing human resources, materials, and personal protective equipment (PPE) needed for these procedures, the high risk of contagion of the team and of postoperative complications in patients with COVID-19. Although it is not a consensus yet, the proposal was to consider postponing elective procedures and surgeries for up to 3 months, provided that no harm was caused to the clinical condition of the patients. More recently, the International Federation of Gynecology and Obstetrics (FIGO) has published a FIGO Statement about guidance for resuming elective surgeries at the current point of the COVID-19 health crisis.[2] The American College of Obstetrics and Gynecology (ACOG) has also drawn up recommendations on how the program directors can support obstetrics and gynecology residents during the COVID-19 pandemic.[3] In Brazil, on 8 May, 2020, the National Medical Residency Commission (CNRM, in the Portuguese acronym), linked to the Ministry of Education, released a Technical Note Draft with recommendations for medical residency programs during the pandemic.[4] Such recommendations derived from guidelines established for medical residencies by CNRM Resolution number 2/2006 and the Competency Framework of each specialty for the redefinition of the rotations and distribution of the workload among activities. The guideline also includes the “Manifestation of the Federal Council of Medicine in relation to the COVID-19 pandemic”, published on 25 March 2020. Its recommendation is that Brazilian physicians remain in their jobs, because “in this position, they will be able to exercise their most relevant role as guardians of life.” The Federal Council of Medicine also deems necessary the provision of PPE for physicians and other health professionals by the government and health authorities, so these professionals can perform their work safely. According to this document, medical residency programs should make its curriculum more flexible to suit the pandemic context. The legislation in force establishes the maximum workload of 60 hours per week per resident, with between 10 and 20% destined to classes and between 80 and 90% to practical activities, already including a maximum of 24 hours on duty. Besides, it provides the resident with a weekly day off. The National Medical Residency Commission recommends the development of the classes within the maximum allowed limit (20% of the total workload) of 12 hours per week. Face-to-face classes must be suspended and developed through virtual meetings using videoconferencing tools. Classes should address themes related to each medical specialty, and issues related to the pandemic. Such topics include the detection, management, and flow for the care of patients with COVID-19, its complications, and individual and collective protection strategies. Also, training for donning and removal of PPE, and orotracheal intubation techniques should be included in the syllabus of medical residencies. The National Medical Residency Commission establishes that in clinical training, the relocation of medical residents during the pandemic should be based on an Incidence Coefficient (number of new cases/million inhabitants) and the classification by the epidemiological complexity level of the Municipality and Health Region of the medical residency program. [Table 1] shows the main recommendations for the workload of the residents in fighting the pandemic according to the incidence of COVID-19 and the epidemiological complexity of the region. For medical specialties related to the care of patients with COVID-19, the entire residency clinical workload can be used with care activities to combat the pandemic. Clinical training in medical residency programs must be redistributed according to the clinical experience of the residents. The resident must practice under supervision, ensuring the maximum use of the training and preserving the patient safe. The reorganization of rotations must consider the availability and learning opportunities in clinical settings of the host institution and of institutions associated with the medical residency program, prioritizing the performance in hospital care and emergency rooms, and always respecting the maximum workload of the residents. After returning to normality, the replacement of the residency program activities that were not developed during the pandemic will be subject to analysis and to a subsequent decision by the National Medical Residency Commission. Medical residents included in the risk group according to criteria established by the Ministry of Health, as well as pregnant women, must communicate their condition to the medical residency program supervisor and the respective Medical Residency Committee (COREME, in the Portuguese acronym) of the hospital. These individuals will be relocated according to the risk of infection or take a leave from clinical settings through sick leave, in which case the relevant medical report should be presented. In case of leave by suspicion or confirmation of COVID-19, regulations established by the Ministry of Health and health services in the states and municipalities must be followed and the resident must comply with the recommended isolation. The COREME must report the absence of the resident as “on sick leave” to the National Medical Residency Commission System (SISCNRM, in the Portuguese acronym) and notify the scholarship manager for the suspension of regular payment. Residents on sick leave must follow the procedure with the National Social Security Institute (Brazilian INSS). Other situations of leave of absence provided for in paragraphs 2, 3, 4 of Art. 4 of law number 12.514/2011 include paternity leave of 5 days and maternity leave of 120 days, extendable for another 60 days in agreement with the institution responsible for the medical residency program. The time required to complete the program must be extended by a period equivalent to the duration of the leave period of the resident. In situations when patient care services and surgical procedures of a medical residency program have been fully suspended, part of the activities should be relocated to other services. If this is not possible, the decision regarding the continuity of the program must be taken in common agreement between the COREME and local health managers. The same recommendation applies to situations in which medical residents have been called upon to act to face the pandemic in other municipalities. The SISCNRM also foresees the probability of interrupting the activities of a medical residency program because services are inadequate or for lack of safety for performing professionals in the face of the pandemic. In such cases, the flow should be: Having exhausted all the possibilities for maintaining the medical residency program, the situation must be communicated to the State Medical Residency Commission (CEREM, in the Portuguese acronym) and the SISCNRM so that the medical residency program authorization act is reviewed following the consequences provided for in the legislation in force. * Text prepared by the members of the National Specialized Commission on Medical Residency and endorsed by the Scientific Board and Presidency of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO).


  • Open Access

    Intrauterine Device Insertion during Cesarean Section in Women without Prenatal Contraception Counseling: Lessons from a Country with High Cesarean Rates

    by Alberto Moreno Zaconeta, Ana Carolina Oliveira, Flavielly Souza Estrela, Thalia Maia Vasconcelos, Paulo Sergio França, Miriam da Silva Wanderley, Angelica Amorim Amato

    Objective The moment of admission for delivery may be inappropriate for offering an intrauterine device (IUD) to women without prenatal contraception counseling. However, in countries with high cesarean rates and deficient prenatal contraception counseling, this strategy may reduce unexpected pregnancies and repeated cesarean sections. Methods This was a prospective cohort study involving 100 women without prenatal contraception counseling. Postplacental IUD was offered after admission for delivery and placed during cesarean. The rates of IUD continuation, uterine perforation, and endometritis were assessed at 6 weeks and 6 months, and the proportion of women continuing with IUD at 6 months was assessed with respect to the number of previous cesareans. Results Ninety-seven women completed the follow-up. The rate of IUD continuation was 91% at 6 weeks and 83.5% at 6 months. The expulsion/removal rate in the first 6 weeks was not different from that between 6 weeks and 6 months (9 vs 9.1%, respectively). There were 2 cases of endometritis (2.1%), and no case of uterine perforation. Among 81 women continuing with intrauterine device after 6-months, 31% had undergone only the cesarean section in which the IUD was inserted, 44% had undergone 2 and 25% had undergone 3 or more cesarean sections. Conclusion Two thirds of the women who continued with IUD at 6 months had undergone 2 or more cesarean sections. Since offering trial of labor is unusual after 2 or more previous cesareans, we believe that offering IUD after admission for delivery may reduce the risk of repeated cesarean sections and its inherent risks.


  • Vasa Previa: A Cautious Approach at Caesarean Section

    by Amanda Gomes, Juliana Rezende, Maria de Fátima Vogt, Alberto Zaconeta